The study was a survey of health professionals who had taken prophylactic oseltamivir after contact with Nobel Influenza A infection (H1N1) patients using the following questions. 1) Why did you take the medication? 2) How long did you take it? 3) Why did you stop taking it? 4) Did the medication cause adverse events? A comparison in terms of compliance rates was made between two groups based on whether the patients were family members or not. There was a statistically significant difference between the two groups (p=0.028). The compliance rate of the group of individuals in contact with family members with Nobel Influenza A infection (H1N1) viruses was significantly higher than that of the other group. The rate of continuing the medication after adverse events tended to higher, but there was no statistically significant difference between the two groups. Therefore, compliance with taking prophylactic oseltamivir was largely affected by the reason for taking the medication. The rate of adverse event occurrence as a result of taking oseltamivir was 16.7%, but all adverse events were minor, i.e., graded one on the general toxicity scale for seriousness of adverse events.
